The FDA has made some modest efforts, but it needs an internal organization that understands and would be an aggressive ...

Over the past decade, the rising cost of insulin epitomized the broader systemic issue of higher healthcare out-of-pocket ...

Sen. Scott Wiener (D-San Francisco) has introduced two bills in the State Senate that could lower prescription drug prices ...

Patients with diabetic DED can experience inflammatory biomarker reductions and sign and symptom improvements with topical insulin.

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Over 66% of U.S. adults use at least one prescription drug, according to data gathered by the Health Policy Institute at ...

Walgreens-Boots Alliance struggles with margin compression, competition, and financial risks. Learn why these challenges make ...

LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / DaVita, a comprehensive kidney care provider, has activated its emergency response plan as devastating wildfires spread across Southern ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Our expert, award-winning staff selects the products we cover and rigorously researches and tests our top picks. If you buy through our links, we may get a commission. Executive Editor David ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...